N-[4-chloro-3-(trifluoromethyl)phenyl]-3-oxobutanamide
N-[4-chloro-3-(trifluoromethyl)phenyl]-3-oxobutanamide
![N-[4-chloro-3-(trifluoromethyl)phenyl]-3-oxobutanamide 结构式](https://img.chemicalbook.com/CAS/20200331/GIF/392721-37-8.gif)
N-[4-chloro-3-(trifluoromethyl)phenyl]-3-oxobutanamide 性质
| 沸点 | 394.2±42.0 °C(Predicted) |
|---|---|
| 密度 | 1.411±0.06 g/cm3(Predicted) |
| 储存条件 | room temp |
| 溶解度 | 二甲基亚砜：>10mg/mL |
| 形态 | 粉末 |
| 酸度系数(pKa) | 10.76±0.46(Predicted) |
| 颜色 | 白色至类白色 |
| 稳定性 | DMSO中的溶液可在-20°下稳定储存3个月。 |
| InChI | 1S/C11H9ClF3NO2/c1-6(17)4-10(18)16-7-2-3-9(12)8(5-7)11(13,14)15/h2-3,5H,4H2,1H3,(H,16,18) |
| InChIKey | GNYIJZMBLZXJEJ-UHFFFAOYSA-N |
| SMILES | CC(=O)CC(=O)Nc1ccc(Cl)c(c1)C(F)(F)F |
N-[4-chloro-3-(trifluoromethyl)phenyl]-3-oxobutanamide 用途与合成方法
|
GLUT4 68 μM (IC 50 ) |
GLUT1
|
Fasentin (0.1-1000 μM; 72 hours) inhibits endothelial, tumour and fibroblast cell growth without inducing cell death.
Fasentin (25-100 μM; 16-24 hours) induces a cell cycle arrest in G0/G1 phase and reduces the cell number in S phase in a dose-dependent manner.
Fasentin (50 μM; 16 hours) alters expression of genes associated with glucose deprivation such as AspSyn and PCK-2.
Fasentin (15, 30, 80 μM; pretreatment 1 hour) induces glucose deprivation, partially blocks glucose uptake in PPC-1, DU145, and U937 cells.
Fasentin (100 μM; 16 hours) does not affect the migratory capability of endothelial cells.
Fasentin (25-100 μM; 16 hours) lowers levels of phospho-ERK in HMECs, indicating a partial inhibition on the ERK signalling pathway, even though the effect is not statistically significant. Fasentin does not inhibit the tyrosine kinase activity of VEGFR2.
Fasentin interacts with a unique site in the intracellular channel of GLUT1.
Cell Viability Assay
| Cell Line: | Three types of endothelial cells ECs (HMEC, human microvascular endothelial cells; HUVEC, human umbilical vein endothelial cells; and BAEC, bovine aortic endothelial cells), three human tumour cell lines (MDA-MB-231 and MCF7 breast carcinoma cells, and HeLa cervix adenocarcinoma cells), and human gingival fibroblasts (HGF) |
| Concentration: | 0.1, 1, 10, 100, 1000 μM |
| Incubation Time: | 72 hours |
| Result: | Inhibited endothelial, tumour and fibroblast cell growth (IC 50 =26.3-111.2 μM) without inducing cell death. |
Cell Cycle Analysis
| Cell Line: | HMECs |
| Concentration: | 25, 50, 100 μM |
| Incubation Time: | 16, 24 hours |
| Result: |
Induced a cell cycle arrest in G0/G1 phase and reduced the cell number in S phase in a dose-dependent manner.
Did not increase the subG1 population. |
RT-PCR
| Cell Line: | PPC-1 cells [2] |
| Concentration: | 50 μM |
| Incubation Time: | 16 hours |
| Result: | Altered expression of genes associated with glucose deprivation such as AspSyn and PCK-2 not FLIP mRNA expression. |
N-[4-chloro-3-(trifluoromethyl)phenyl]-3-oxobutanamide 价格(试剂级)
| 更新日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
|---|---|---|---|---|---|
| 2026-06-05 | HY-101849R | N-[4-chloro-3-(trifluoromethyl)phenyl]-3-oxobutanamide | 392721-37-8 | 5 mg | 1400 |
| 2026-06-05 | HY-101849R | N-[4-chloro-3-(trifluoromethyl)phenyl]-3-oxobutanamide | 392721-37-8 | 10 mg | 2200 |
